{"nctId":"NCT01164202","briefTitle":"Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer","startDateStruct":{"date":"2010-07"},"conditions":["Liver Cancer"],"count":78,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Procedure: transarterial chemoembolization"]},{"label":"Sunitinib","type":"EXPERIMENTAL","interventionNames":["Drug: sunitinib malate","Procedure: transarterial chemoembolization"]}],"interventions":[{"name":"sunitinib malate","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"transarterial chemoembolization","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically confirmed hepatocellular carcinoma or liver tumor responding to the Barcelona criteria\n* Child-Pugh score of 5-6 (Class A)\n* Tumor suitable for transarterial chemoembolization (one or more planned courses allowed)\n* Tumor not suitable for surgical resection\n* No extrahepatic metastases, including cerebral metastases\n\nPATIENT CHARACTERISTICS:\n\n* ECOG performance status 0-2\n* Absolute neutrophil count ≥ 1.5 x 10\\^9/L\n* Platelet count ≥ 100 x 10\\^9/L\n* Hemoglobin ≥ 10 g/dL\n* PT ≥ 50%\n* Creatinine ≤ 120 μmol/L\n* Bilirubin normal\n* ALT/AST ≤ 3.5 times upper limit of normal (ULN)\n* Alkaline phosphatases ≤ 4 times ULN\n* Fibrinogen ≥ 1.5 g/L\n* Not pregnant or nursing\n* Fertile patients must use effective contraception\n* No portal vein thrombosis\n* Able to comply with scheduled follow-up and management of toxicity\n* No uncontrolled hypertension or requiring ≥ 2 classes of antihypertensive drugs\n* No concomitant disease or uncontrolled severe disease\n* No contraindications to the vascular occlusion procedure\n* No prior or concurrent malignancy within the past 5 years, except adequately treated cone-biopsied carcinoma in situ of the cervix or basal cell carcinoma of the skin\n* No psychiatric disability or social, family, or geographic reason for which the patient may not be followed regularly\n\nPRIOR CONCURRENT THERAPY:\n\n* At least 7 days since prior CYP3A4 inhibitors or inducers\n* At least 3 months since prior radiofrequency ablation\n* No prior chemotherapy\n* No prior sunitinib, sorafenib, or any other inhibitors of angiogenesis\n* No concurrent participation in another trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"120 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Patients With Occurrence of Severe Bleeding and/or Liver Failure","description":"The number of patients with at least one bleed and/or liver failure by treatment group","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.88","spread":null},{"groupId":"OG001","value":"2.78","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival is defined as the time from the date of randomization to the date of death (from any cause).\n\nPatients lost to follow-up or alive at the time of analysis are censored at the last news date or the point date.\n\nThis time is used to calculate the median follow-up time.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.5","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease-free Survival","description":"Disease-free survival is defined as the time interval between randomization and local or distant relapse or second cancer or death (all causes). Alive patients are censored at the last follow-up.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":39},"commonTop":["ASAT","ALAT","Bilirubine","Platelets","Neutrophiles"]}}}